Key takeaways
- Eli Lilly controls 70% of the expanding Medicare GLP-1 pilot program, according to CEO David Ricks.
- The federal Medicare pilot program has rapidly scaled to reach 700,000 senior beneficiaries.
- High institutional demand for brand-name drugs continues to squeeze supply for retail cash-paying buyers.
- Cash buyers are increasingly turning to online telehealth and compounded options to bypass high retail prices.
What happened
Eli Lilly Chief Executive Officer David Ricks announced that the pharmaceutical giant now controls approximately 70% of the rapidly expanding Medicare GLP-1 pilot program. The federal insurance initiative, which provides coverage for select cardiovascular indications in seniors, has quickly scaled to reach 700,000 Medicare beneficiaries.
Why it matters
This dominant market share has massive implications for the broader U.S. GLP-1 marketplace, particularly for cash-paying consumers. As Eli Lilly and competitor Novo Nordisk funnel a substantial portion of their brand-name supply to satisfy expanding Medicare coverage, retail pharmacy shelves face sustained pressure.
For the millions of Americans who do not qualify for Medicare coverage or whose commercial insurance plans exclude weight-loss medications, accessing brand-name drugs like Zepbound and Wegovy remains exceptionally difficult. The massive volume absorbed by the Medicare pilot program means that cash-paying buyers are increasingly pushed away from traditional retail pharmacies and toward online telehealth providers and compounded alternatives to bypass persistent brand-name shortages and high out-of-pocket prices.
What the data says
The expansion of the Medicare GLP-1 pilot program highlights several critical figures:
- 700,000 Seniors Enrolled: The federal program has rapidly scaled to support nearly three-quarters of a million Medicare beneficiaries.
- 70% Market Share: Eli Lilly's therapies (including tirzepatide) comprise the vast majority of the pilot program's prescription volume, according to CEO David Ricks.
- Supply Allocation: By capturing such a large share of the government-backed program, Eli Lilly is prioritizing massive institutional contracts, which naturally limits the surplus volume available for the commercial retail market.
For patients paying without insurance, brand-name GLP-1 medications carry retail list prices exceeding $1,000 per month. Without access to government programs or commercial coverage, these prices are mathematically out of reach for many household budgets.
How it compares
The dynamics of the Medicare program starkly contrast with the options available to self-pay consumers. While Medicare beneficiaries in this program receive heavily subsidized brand-name therapies, cash-pay consumers must navigate a highly competitive digital health space to find affordable care.
Brand-name Zepbound and Wegovy command list prices of approximately $1,059 and $1,349 per month, respectively, when purchased at retail pharmacies without coverage. In contrast, online health platforms offer compounded semaglutide and compounded tirzepatide at much lower price points.
For example, digital clinics frequently offer compounded GLP-1 medications starting between $150 and $300 per month, which includes both the medical consultation and the shipped medication. Some aggressive market entrants have cut prices even further. You can compare the top clinical options and pricing structures on our providers directory or review the cheapest telehealth GLP-1 options to see how retail cash prices compare to digital programs.
How this fits the bigger picture
The federal government's increasing absorption of brand-name GLP-1 supply directly influences how private-pay patients manage their long-term health. Because clinical evidence indicates that stopping GLP-1s raises heart attack and stroke risk by 22 percent, maintaining a reliable, uninterrupted supply of medication is a critical health priority.
When brand-name shortages occur due to massive institutional demand like Medicare, patients cannot simply pause therapy without risking significant clinical setbacks. This supply squeeze has accelerated the shift toward alternative telehealth ecosystems.
While brand-name drugmakers struggle to meet demand, the private telehealth market is experiencing rapid price competition. For instance, as detailed in our coverage of how Oak launches $119 compounded GLP-1 plans, clinical platforms are drastically lowering the barrier to entry for cash-pay patients. This dual-track market—where insurance-covered patients receive brand-name drugs and cash-paying patients utilize compounders—is becoming the permanent status quo for U.S. weight-loss care.
To find the right pathway for your budget and medical history, you can use our questionnaire to evaluate which telehealth services fit your specific goals.
What happens next
As Medicare continues to evaluate its budget allocations and coverage criteria for obesity and cardiovascular care, the pilot program is expected to face continued pressure to expand further. Eli Lilly and Novo Nordisk are both actively investing billions of dollars to scale up their manufacturing plants, hoping to resolve the bottleneck.
However, until brand-name supply fully catches up with both government-subsidized programs and private demand, the reliance on compounding pharmacies and telehealth providers will remain a primary avenue for millions of American consumers.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication regimen.